Hims and Roman are telehealth companies that sell prescription and nonprescription products to treat erectile dysfunction (ED), hair loss, and premature ejaculation (PE). Both ED and hair loss can ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%, and achieved a full year of operating and net income profitability. Despite strong fundamentals, HIMS stock price has ...

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth company. A big part of that is related to its Super Bowl LIX ad ...

Hims & Hers Health, Inc. (HIMS) shares rallied 27.7% in the last trading session to close at $59.18. This move can be attributable to notable volume with a higher number of shares being traded ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site. The ad also hit a nerve with the pharma industry, lawmakers and some industry groups. The ad, called ...

Fenty Hair by Rihanna has developed a new product, and it's the Water Boi reparative leave-in detangling conditioner spray.

Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticized the ...

Hims & Hers has capitalized on the outsize consumer demand for obesity drugs. (Hims & Hers Health) Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or side effect disclosures. These compounded drugs, unlike generics, are not ...